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2) The study is not designed/presented in the way to give a definite answer in respect to the mass H.pylori screening / eradication strategy; therefore recommendations cannot be given in this respect. 3) From the practical point -simultaneous use of a gFOBT and a FIT is not rational, and will probably be never implemented in any screening program (this is not recommended by the authors, but being used in the design) 4) The standard gFOBT testing includes the analysis of 3 consecutive stool samples, while the current study was using only one. Naturally, with more samples the proportion of positive tests will raise. Although this has briefly been mentioned in the Discussion (p.36), but this could have a major impact on the results in general. 5) There should be a consistency between the set Objectives and the title. Currently the Objective is addressing only upper GI lesions (what is corresponding to the results) while the title of the manuscript is mentioning both: lower and upper GI lesions 6) The text could be shortened or partly moved to Supplementary information.
The minor comments include the following: 1) Introduction. P.9, last paragraph. Should be abbreviated, unrelated information withdrawn. The rationale of combining the 2 tests has to be proven. 2) Details on the test performance that are based on the previous studies, bowel-preps and similar could be moved to Supplementary information 3) Immunochemical tests could be abbreviated as "FIT" 4) Discussion, p. 36. Please note that neither Belarus nor the Baltic States are bordering to Asia.
REVIEWER
Sugano, Kentaro Jichi Medical School, Department of Medicine REVIEW RETURNED 04-Sep-2013 GENERAL COMMENTS This is a sort of "proof-of-concept" study to examine a performance of a combination of stool tests for detecting both upper and lower gastrointestinal (GI) lesions. A large number of subjects were involved for whom both upper and lower endoscopic diagnosis were completed. They found that a combination of fecal occult-blood test (FOBT) and Helicobacter pylori (H. pylori) stool antigen test was useful for detecting both upper and lower GI lesions. Further validation study, though with a different cohort population, supported the advantage of the combination to detect additional upper GI lesions. However, the feasibility of this screening method would be limited in many countries where the resources for upper GI endoscopy and colonoscopy are limited.
Some comments 1. For adopting the proposed strategy for gastrointestinal cancer screening, the cost-effectiveness estimation is essential. Unfortunately, no such consideration was given in this study. 5. The gender balance in the validation cohort was quite different from the cancer screening cohort, thereby compromising the validity of using this cohort as validation. Indeed, very high peptic ulcer rate in the H. pylori positive subjects is surprising. How many of these elderly women were using non-steroidal anti-inflammatory drugs? 6. Authors did not mention whether the diagnosis was based on biopsies. It is strange that no cases with gastric adenomas were included in the results.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1:
The manuscript entitled "Accuracy of fecal occult-blood tests and Helicobacter pylori stool antigen test for detection of lower and upper gastrointestinal lesions" by Lee et al. is presenting data on a large and well designed study to evaluate the performance of two different FOBTs (FIT and a guaiac FOBT) and H. pylori stool antigen test for detecting upper and lower GI lesions. The study has been conducted in two large-size study populations -a deviation cohort (mixedinvited plus hospital patient-based) and a validation cohort. The latter (>3600 community-based cohort) is of major interest since these are results could be translated to general screening settings. This should be mentioned that the data on the prevalence of upper GI lesions in patients with a positive FOBT result is important (the authors are appropriately indication the inconsistency of the available knowledge), still also this study does not provide very solid information in this matter. Although the study is designed, study subject estimates and statistics is appropriate, the presentation of the results and conclusion are raising some concern. The major comments include the following:
(1) gFOBT and H. pylori antigen test are each addressing completely different lesions of the GI tract. Although the lesion detection rate in the upper GI part at the occasion of a positive FOBT is important, I cannot agree on the direct comparison of the above test performance when patients with a positive FIT test and positive colonoscopy are excluded (statement that "H. pylori stool antigen is more accurate than the guaiac-based test for screening of upper GI lesions"). Re: To respond to this valuable comment, we first have provided the diagnostic accuracy of gFOBT in detection of upper gastrointestinal lesions by taking subjects with positive FIT and positive colonoscopy into account. The results are shown in Table 2 (page 22) . In fact, the result was similar to our previous findings. Second, we also understood that the lesions detected by the gFOBT and HPSA might be somewhat different while that is the reason why we did a series of subgroup analyses in Table 3 (page 26). We have described this rationale in Statistical Analysis (page 16, line 3-6).
(2) The study is not designed/presented in the way to give a definite answer in respect to the mass H. pylori screening/eradication strategy; therefore recommendations cannot be given in this respect. Re: Agree. According to this valuable comment, we have modified our final conclusion (Abstract, page 6, line 7-10). We have also indicated that the present study was a diagnostic accuracy study (page 5, line 5-6). We also modified the tone in proposing the strategy of using two stool tests for pandetection (Discussion, page 36, line 5-9).
(3) From the practical point -simultaneous use of a gFOBT and a FIT is not rational, and will probably be never implemented in any screening program (this is not recommended by the authors, but being used in the design) Re: Although the gFOBT and FIT have been used to detect colorectal lesions, there is no previous attempt to screen upper gastrointestinal tract lesions. The hypothesis of combining gFOBT and FIT has been raised in several previous publications (reference 7 and 8). This rationale has been detailed in Introduction (page 8, 2nd paragraph, line 6-12). In our population, the prevalence rate of UGI lesions is high. We aimed to identify a method to detect UGI lesions using commercially available stool tests so we believe this hypothesis testing is reasonable. Although such an approach is rare to be implemented in service screening programs, combination of stool tests is commonly used in diagnostic accuracy studies (reference 21 and 22). In our study, the simultaneous uptake rate of gFOBT and FIT was above 90% (page 17, line 12-13), which also indicated that this approach was not impractical.
(4) The standard gFOBT testing includes the analysis of 3 consecutive stool samples, while the current study was using only one. Naturally, with more samples the proportion of positive tests will raise. Although this has briefly been mentioned in the Discussion (p.36), but this could have a major impact on the results in general. Re: In our study, we used one-specimen method for the "highly sensitive" gFOBT; in fact, this is a commercialized product (page 11, line 2: Hemoccult SENSA Single Slides; Beckman Coulter, Inc., USA). We found its sensitivity was similar to that of FIT in detecting lower gastrointestinal lesions, indicating that such a one-specimen method is also an option (page 35, line 13-16). Nonetheless, we do agree that we may have underestimated the sensitivity of the guaiac-based test for detecting upper gastrointestinal lesions as occult blood was more likely intermittent and unevenly distributed in the stool, more requiring multiple samples. This limitation has been detailed in Discussion (page 35, line 16-19 and page 36, line 1).
(5) There should be a consistency between the set Objectives and the title. Currently the Objective is addressing only upper GI lesions (what is corresponding to the results) while the title of the manuscript is mentioning both: lower and upper GI lesions Re: Agree. Accordingly, we have modified the title of our study (page 1).
(6) The text could be shortened or partly moved to Supplementary information. Re: The supplement is focusing on the sensitivity analysis. We have shortened the manuscript and the word count is now keeping with the Journal style.
The minor comments include the following:
(1) Introduction. P.9, last paragraph. Should be abbreviated, unrelated information withdrawn. The rationale of combining the 2 tests has to be proven. Re: Agree. We have made this paragraph concise and added the secondary aim to evaluate the feasibility of combining two stool tests in the real world setting (page 9, line 4-5).
(2) Details on the test performance that are based on the previous studies, bowel-preps and similar could be moved to Supplementary information. Re: Actually, the supplement is focusing on the sensitivity analysis. The test performance of HPSA (page 11, line 12-13) and the bowel-preps (page 11, line 19 to page 12, line 1) are very briefly mentioned so we retained them in the main text.
(3) Immunochemical tests could be abbreviated as "FIT" Re: Agree. We have used some abbreviations in the revised manuscript, including the use of FIT.
(4) Discussion, p. 36. Please note that neither Belarus nor the Baltic States are bordering to Asia. Re: Agree. Also to respond to the reviewer's comment 2, we have modified this statement (page 34, line 18-19).
Reviewer 2: This is a sort of "proof-of-concept" study to examine a performance of a combination of stool tests for detecting both upper and lower gastrointestinal (GI) lesions. A large number of subjects were involved for whom both upper and lower endoscopic diagnosis were completed. They found that a combination of fecal occult-blood test (FOBT) and Helicobacter pylori (H. pylori) stool antigen test was useful for detecting both upper and lower GI lesions. Further validation study, though with a different cohort population, supported the advantage of the combination to detect additional upper GI lesions. However, the feasibility of this screening method would be limited in many countries where the resources for upper GI endoscopy and colonoscopy are limited.
Some comments (1) For adopting the proposed strategy for gastrointestinal cancer screening, the cost-effectiveness estimation is essential. Unfortunately, no such consideration was given in this study. Re: Our study is a diagnostic accuracy study (Abstract, page 5, line 5). The cost-effectiveness analysis is beyond the scope of the present study. However, we do agree with you that further costeffectiveness analyses are needed to evaluate the benefit of our proposed strategy for gastrointestinal cancer screening. Accordingly, we have added additional comments in Discussion (page 36, line 13-17).
(2) Secondly, inclusion of H. pylori infection survey with stool antigen test would result in a large number of positive subjects requiring further endoscopic examinations. Indeed, about 25% (24.2 % in screening group) of enrolled subjects had to take further endoscopy in this study which meant almost twice more endoscopic examinations would be required as compared to FOBT group (11.3%). This strategy requiring a large number of endoscopic examinations seems to be impractical in many countries where routine endoscopic examinations are expensive and only limited number of experienced endoscopists are available. Re: Agree. We have added this point as one of our study limitations (page 36, line 5-9) and suggested that further risk-score based approach with targeted endoscopy may be one potential solution. We have cited a new reference 53 to support this idea.
(3) A better performance of two consecutive stool occult-blood tests rather than single one for detecting colon lesions was well-documented. Why authors chose a single test for colorectal cancer screening? Obviously, colorectal cancer incidence seems to be higher in Taiwan, so more focused efforts should be made to detect colon cancer. Re: The primary aim of this study is to identify an accurate method for upper gastrointestinal tract lesions (Introduction, page 9, 1st paragraph). The current policy of our nation-wide colorectal cancer screening is to provide one-day method with FIT. To increase the sensitivity of FIT in detecting lower gastrointestinal lesions, the two-day method of FIT is known to be one option and this approach has been under enthusiastic investigation in Taiwan; however, this is beyond the scope of our study. Regarding guaiac-based testing, we do agree that we may have underestimated the sensitivity of gFOBT in detecting UGI lesions and this limitation has been detailed in Discussion (page 35, line 13-19 and page 36, line 1).
(4) Authors added hospital-based cohort to the cancer screening cohort, which might have skewed the endoscopic detection by artificially increasing positive cases. Please state the reason why authors added this cohort.
Re: This is due to the low number of cancer; we have provided the rationale of this recruitment process in Methods (page 10, line 2-7). We agreed that this would increase the number of positive cases; however, we aimed to determine the sensitivity and specificity of the stool tests and the sensitivity and specificity are not dependent on the number of positive cases.
(5) The gender balance in the validation cohort was quite different from the cancer screening cohort, thereby compromising the validity of using this cohort as validation. Indeed, very high peptic ulcer rate in the H. pylori positive subjects is surprising. How many of these elderly women were using nonsteroidal anti-inflammatory drugs? Re: The high female proportion in the community study is related to the design of the integrated multiple cancer screening program in Chunghwa County since 2005. The determination of invitation list was also based on the screening tests for female cancers. Although we have adjusted the age and gender distributions of our community population in the evaluation of test reproducibility, we do agree with you that self-selection bias could not be excluded. We have described this issue in more details in Methods (page 13, line 9-11) and also in Discussion (page 36, line 10-13).
The prevalence rate of regular use of NSAID/aspirin in our community population is about 8% and we have provided this information in Discussion (page 34, line 11). We do agree with you that, in addition to the long-term H. pylori infection, the increased use of NSAID/aspirin in our aged population may also attribute to the high prevalence of peptic ulcers in our community population. We have added this important comment into Discussion (page 34, line 10-13) and cited a new reference 39 to support the potential synergistic effect between NSAID/aspirin and H. pylori on the risk of peptic ulcers.
(6) Authors did not mention whether the diagnosis was based on biopsies. It is strange that no cases with gastric adenomas were included in the results. Re: The endoscopic diagnosis was confirmed by the pathologic results under the routine practice; we have added this information into Methods (page 13, line 16-17). In the present study, no gastric adenoma was reported.
